Work

Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.4_suppl.564

Authors: Anthony B. El-Khoueiry, Richard D. Kim, William P. Harris, Max W. Sung, Dirk Waldschmidt, Syma Iqbal, Xiaojing (Amily) Zhang, Keiko Nakajima, Peter R. Galle

Institutions: University of Southern California, USC Norris Comprehensive Cancer Center, Moffitt Cancer Center, Seattle Cancer Care Alliance, University of Washington, Tisch Cancer Institute, University Hospital Cologne, Bayer (United States), University Medical Center of the Johannes Gutenberg University Mainz

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3004564992

Cites:

Cited by: 24

Related to: 10